Anavex Life Sciences (AVXL) Net Cash Flow Growth (3y) (2013 - 2025)
Anavex Life Sciences (AVXL) Net Cash Flow Growth (3y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 32.17% |
| 10 | Anavex Life Sciences | 223.91 Mn | 92.16 Mn | - | 93.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 93.72% |
| Sep 30, 2025 | 32.94% |
| Jun 30, 2025 | -367.23% |
| Mar 31, 2025 | -62.34% |
| Dec 31, 2024 | -128.12% |
| Sep 30, 2024 | -6.41% |
| Jun 30, 2024 | -26.15% |
| Mar 31, 2024 | -29.14% |
| Dec 31, 2023 | -33.90% |
| Sep 30, 2023 | -62.96% |
| Jun 30, 2023 | 8.53% |
| Mar 31, 2023 | 135.11% |
| Dec 31, 2022 | -45.02% |
| Sep 30, 2022 | -84.85% |
| Jun 30, 2022 | -27.65% |
| Mar 31, 2022 | 55.32% |
| Dec 31, 2021 | 24.29% |
| Sep 30, 2021 | -23.46% |
| Jun 30, 2021 | 681.75% |
| Mar 31, 2021 | 140.53% |